Latest Insider Transactions at Ardelyx, Inc. (ARDX)
This section provides a real-time view of insider transactions for Ardelyx, Inc. (ARDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARDELYX, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARDELYX, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 21
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,855
-1.27%
|
$33,985
$7.81 P/Share
|
|
May 21
2024
|
Laura A Williams Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,794
-1.29%
|
$33,558
$7.81 P/Share
|
|
May 21
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
31,484
-2.4%
|
$220,388
$7.81 P/Share
|
|
May 21
2024
|
Justin A Renz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,167
-1.69%
|
$36,169
$7.81 P/Share
|
|
May 21
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
6,927
-3.36%
|
$48,489
$7.81 P/Share
|
|
May 21
2024
|
Robert Blanks Officer |
SELL
Open market or private sale
|
Direct |
4,855
-1.32%
|
$33,985
$7.81 P/Share
|
|
May 21
2024
|
Robert Ora Felsch Officer |
SELL
Open market or private sale
|
Direct |
3,485
-3.53%
|
$24,395
$7.81 P/Share
|
|
May 14
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.23%
|
$21,000
$7.99 P/Share
|
|
May 06
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
284,170
-32.54%
|
$2,273,360
$8.88 P/Share
|
|
May 06
2024
|
Elizabeth A Grammer Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
219,937
+20.46%
|
$219,937
$1.87 P/Share
|
|
May 06
2024
|
Robert Ora Felsch Officer |
SELL
Open market or private sale
|
Direct |
207,988
-43.39%
|
$1,663,904
$8.81 P/Share
|
|
May 06
2024
|
Robert Ora Felsch Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
119,101
+17.34%
|
$119,101
$1.8 P/Share
|
|
May 03
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
45,000
-14.38%
|
$405,000
$9.0 P/Share
|
|
May 03
2024
|
Laura A Williams Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
39,949
-9.74%
|
$319,592
$8.35 P/Share
|
|
May 03
2024
|
Laura A Williams Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.82%
|
$0
$0.99 P/Share
|
|
Apr 29
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.24%
|
$180,000
$6.4 P/Share
|
|
Apr 29
2024
|
Michael Raab President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.19%
|
$0
$0.99 P/Share
|
|
Apr 15
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
7,500
-0.57%
|
$52,500
$7.06 P/Share
|
|
Apr 01
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
1,518
-0.12%
|
$10,626
$7.31 P/Share
|
|
Mar 25
2024
|
Mike Kelliher |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+50.0%
|
-
|
|
Mar 20
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
86,000
-21.55%
|
$602,000
$7.73 P/Share
|
|
Mar 15
2024
|
Robert Blanks Officer |
SELL
Bona fide gift
|
Direct |
1,000
-0.27%
|
-
|
|
Feb 26
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
5,183
-2.86%
|
$46,647
$9.2 P/Share
|
|
Feb 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
2,294
-1.25%
|
$18,352
$8.75 P/Share
|
|
Feb 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,017
-1.31%
|
$40,136
$8.75 P/Share
|
|
Feb 20
2024
|
Justin A Renz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,341
-1.72%
|
$42,728
$8.75 P/Share
|
|
Feb 20
2024
|
Laura A Williams Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,803
-1.25%
|
$38,424
$8.75 P/Share
|
|
Feb 20
2024
|
Robert Ora Felsch Officer |
SELL
Open market or private sale
|
Direct |
2,352
-1.26%
|
$18,816
$8.75 P/Share
|
|
Feb 20
2024
|
Susan Rodriguez Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,928
-1.51%
|
$55,424
$8.75 P/Share
|
|
Feb 20
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
4,432
-1.1%
|
$35,456
$8.75 P/Share
|
|
Feb 20
2024
|
Robert Blanks Officer |
SELL
Open market or private sale
|
Direct |
5,017
-1.34%
|
$40,136
$8.75 P/Share
|
|
Feb 20
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
22,917
-1.71%
|
$183,336
$8.75 P/Share
|
|
Feb 08
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
15,344
-3.84%
|
$138,096
$9.18 P/Share
|
|
Jan 16
2024
|
Laura A Williams Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,750
+23.58%
|
-
|
|
Jan 16
2024
|
Michael Raab President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
475,000
+26.13%
|
-
|
|
Jan 16
2024
|
Justin A Renz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
127,750
+29.17%
|
-
|
|
Jan 16
2024
|
Susan Rodriguez Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,750
+19.7%
|
-
|
|
Jan 16
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
70,120
+27.66%
|
-
|
|
Jan 16
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,750
+22.02%
|
-
|
|
Jan 16
2024
|
Robert Blanks Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,750
+23.2%
|
-
|
|
Jan 16
2024
|
Robert Ora Felsch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,120
+27.25%
|
-
|
|
Jan 16
2024
|
Elizabeth A Grammer Officer |
BUY
Grant, award, or other acquisition
|
Direct |
127,750
+24.05%
|
-
|
|
Jan 08
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
30,000
-9.48%
|
$180,000
$6.64 P/Share
|
|
Dec 26
2023
|
Justin A Renz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
225,000
-55.22%
|
$1,350,000
$6.36 P/Share
|
|
Dec 26
2023
|
Justin A Renz Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+15.55%
|
$0
$0.99 P/Share
|
|
Dec 18
2023
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,675
-1.76%
|
$34,050
$6.07 P/Share
|
|
Dec 14
2023
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,000
-2.13%
|
$35,000
$5.55 P/Share
|
|
Dec 11
2023
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
50,000
-15.35%
|
$250,000
$5.08 P/Share
|
|
Dec 08
2023
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
20,000
-5.73%
|
$100,000
$5.27 P/Share
|
|
Dec 05
2023
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,272
-2.86%
|
$51,360
$5.0 P/Share
|